

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 02/27/2006

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/628,673		07/28/2003	William Wayne Cimino	2171CON	7109	
	7590	02/27/2006		EXAMINER		
Chief Patent	Counse	el	WILLIAMS, CATHERINE SERKE			
United States	Surgical	!		D. D. D. D. C. D.		
a Division of Tyco Healthcare Group LP				ART UNIT	PAPER NUMBER	
150 Glover A	venue	-	3763			
Norwalk, CT	06856				<u></u>	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary The MAILING DATE of this communication app Period for Reply		CIMINO ET AL. Art Unit 3763 orrespondence address							
•	Catherine S. Williams ears on the cover sheet with the c	3763							
	ears on the cover sheet with the c								
		orrespondence address							
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DATE of the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period we Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	l. ely filed the mailing date of this communication. D (35 U.S.C. § 133).							
Status									
1) Responsive to communication(s) filed on 30 No	ovember 2005.								
	action is non-final.								
· 	,—								
closed in accordance with the practice under E	· ·								
Disposition of Claims									
4)⊠ Claim(s) 1-4 6-13 16-22 and 25-27 is/are pend	ing in the application								
4)☑ Claim(s) <u>1-4,6-13,16-22 and 25-27</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration.									
	5)⊠ Claim(s) <u>10-13,16-22 and 25-27</u> is/are allowed.								
6) Claim(s) <u>1-4 and 7-9</u> is/are rejected.									
7) Claim(s) 6 is/are objected to.									
8) Claim(s) are subject to restriction and/or election requirement.									
Application Papers									
9)☐ The specification is objected to by the Examine	r.	•							
10) ☐ The drawing(s) filed on is/are: a) ☐ acce	epted or b) \square objected to by the $\mathfrak k$	examiner.							
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).							
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.							
Priority under 35 U.S.C. § 119									
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority documents application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati ity documents have been receive i (PCT Rule 17.2(a)).	on No d in this National Stage							
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 11120 05	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:								

Art Unit: 3763

DETAILED ACTION

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-4 and 7-9 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-7 of U.S. Patent No. 6,602,227. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are a broad recitation of the patented claims. All the elements of the instant claims can be found in claims 1-7 of Patent No. 6,602,227. The difference between the instant claims and the patented claims is that the patented claims include many more elements and is thus much more specific. The invention of the patented claims is in effect a "species" of the "generic" invention of the instant claims. It has been held that the generic invention is "anticipated" by the "species". See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993).

Application/Control Number: 10/628,673

Art Unit: 3763

Allowable Subject Matter

Page 3

Claims 10-13, 16-22 and 25-27 are allowed.

Claim 6 is objected to as being dependent upon a rejected base claim, but would be

allowable if rewritten in independent form including all of the limitations of the base claim and

any intervening claims.

Conclusion

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Catherine S. Williams whose telephone number is 571-272-4970.

The examiner can normally be reached on Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Nicholas D. Lucchesi can be reached on 571-272-4977. The fax phone number for

the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Catherine S. Williams

ui S. Wilai

February 21, 2006